Literature DB >> 34302351

Clinical predictive models of invasive Candida infection: A systematic literature review.

Adriana M Rauseo1, Abdullah Aljorayid1,2, Margaret A Olsen1, Lindsey Larson1, Kim L Lipsey3, William G Powderly1, Andrej Spec1.   

Abstract

Clinical predictive models (CPM) serve to identify and categorize patients into risk categories to assist in treatment and intervention recommendations. Predictive accuracy and practicality of models varies depending on methods used for their development, and should be evaluated. The aim of this study was to summarize currently available CPM for invasive candidiasis, analyze their performance, and assess their suitability for use in clinical decision making. We identified studies that described the construction of a CPM for invasive candidiasis from PubMed/MEDLINE, EMBASE, SCOPUS, Web of Science, Cochrane Library databases, and Clinicaltrials.gov. Data extracted included: author, data source, study design, recruitment period, characteristics of study population, outcome types, predictor types, number of study participants and outcome events, modelling method, and list of predictors used in the final model. Calibration and discrimination in the derivative datasets were used to assess the performance of each model. Ten articles were identified in our search and included for full text review. Five models were developed using data from ICUs, and five models included all hospitalized patients. The findings of this review highlight the limitations of currently available models to predict invasive candidiasis, including lack of generalizability, difficulty in everyday clinical use, and overly optimistic performance. There are significant concerns regarding predictive performance and usability in every day practice of existing CPM to predict invasive candidiasis.
© The Author(s) 2021. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.

Entities:  

Keywords:  zzm321990 Candidazzm321990 ; candidemia; clinical predictive model; mortality; risk factors

Mesh:

Year:  2021        PMID: 34302351      PMCID: PMC8604268          DOI: 10.1093/mmy/myab043

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   3.747


  44 in total

1.  Generalizability of clinical studies conducted at tertiary care medical centers: a population-based analysis.

Authors:  P M Layde; S K Broste; N Desbiens; M Follen; J Lynn; D Reding; H Vidaillet
Journal:  J Clin Epidemiol       Date:  1996-08       Impact factor: 6.437

2.  Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy.

Authors:  J Concato; P Peduzzi; T R Holford; A R Feinstein
Journal:  J Clin Epidemiol       Date:  1995-12       Impact factor: 6.437

3.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

Authors:  S Ascioglu; J H Rex; B de Pauw; J E Bennett; J Bille; F Crokaert; D W Denning; J P Donnelly; J E Edwards; Z Erjavec; D Fiere; O Lortholary; J Maertens; J F Meis; T F Patterson; J Ritter; D Selleslag; P M Shah; D A Stevens; T J Walsh
Journal:  Clin Infect Dis       Date:  2001-11-26       Impact factor: 9.079

4.  Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study.

Authors:  Daniel H Kett; Elie Azoulay; Pablo M Echeverria; Jean-Louis Vincent
Journal:  Crit Care Med       Date:  2011-04       Impact factor: 7.598

5.  Twenty-two years of candidaemia surveillance: results from a Norwegian national study.

Authors:  L Hesstvedt; P Gaustad; C T Andersen; E Haarr; R Hannula; H H Haukland; N-O Hermansen; K W Larssen; H Mylvaganam; T E Ranheim; P Sandven; I Nordøy; A Kanestrøm; C Grub; A Onken; C Thielsen; D Skaare; S Tofteland; L-J Sønsteby; R Hjetland; R Hide; E Vik; A Kümmel; S Åsheim
Journal:  Clin Microbiol Infect       Date:  2015-06-18       Impact factor: 8.067

6.  What do we mean by validating a prognostic model?

Authors:  D G Altman; P Royston
Journal:  Stat Med       Date:  2000-02-29       Impact factor: 2.373

7.  MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting.

Authors:  Luis Ostrosky-Zeichner; Shmuel Shoham; Jose Vazquez; Annette Reboli; Robert Betts; Michelle A Barron; Mindy Schuster; Marc A Judson; Sanjay G Revankar; Juan Pablo Caeiro; Julie E Mangino; David Mushatt; Roger Bedimo; Alison Freifeld; Minh Hong Nguyen; Carol A Kauffman; William E Dismukes; Andrew O Westfall; Jeanna Beth Deerman; Craig Wood; Jack D Sobel; Peter G Pappas
Journal:  Clin Infect Dis       Date:  2014-02-18       Impact factor: 9.079

8.  Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme.

Authors:  M C Arendrup; E Dzajic; R H Jensen; H K Johansen; P Kjaeldgaard; J D Knudsen; L Kristensen; C Leitz; L E Lemming; L Nielsen; B Olesen; F S Rosenvinge; B L Røder; H C Schønheyder
Journal:  Clin Microbiol Infect       Date:  2013-04-22       Impact factor: 8.067

9.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Authors:  Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

10.  Comparison of techniques for handling missing covariate data within prognostic modelling studies: a simulation study.

Authors:  Andrea Marshall; Douglas G Altman; Patrick Royston; Roger L Holder
Journal:  BMC Med Res Methodol       Date:  2010-01-19       Impact factor: 4.615

View more
  1 in total

1.  Machine Learning in Infectious Disease for Risk Factor Identification and Hypothesis Generation: Proof of Concept Using Invasive Candidiasis.

Authors:  Lisa M Mayer; Jeffrey R Strich; Sameer S Kadri; Michail S Lionakis; Nicholas G Evans; D Rebecca Prevots; Emily E Ricotta
Journal:  Open Forum Infect Dis       Date:  2022-08-03       Impact factor: 4.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.